Clinical OMICS

JUL-AUG 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1138741

Contents of this Issue

Navigation

Page 50 of 51

Managing Multiple Biomarker Therapeutic Development For the past two decades, the paradigm in the field has been "one biomarker, one drug," leading to the development of many targeted therapies and companion diagnostics. As molecular profiling of various cancer types expands, we imagine the use of multiple biomarkers for a combination therapy, like a targeted therapy and immunotherapy together, or even for a monotherapy. In this roundtable our panelists will discuss assessing the validity of biomarkers to inform drug development and potential combination therapies. Key considerations include predictive testing of biomarkers, analytical methods, drug-diagnostic co-development and potential reimbursement considerations. Dr. Kelly Sullivan, Solutions Manager, N-of-One (a QIAGEN Company) will moderate the discussion with Jeffrey Waldron, Executive Director, Precision Medicine Connective, and Dr. Diana Merino, Science Policy Analyst at Friends of Cancer Research. The panel discussion will be followed by an audience Q&A. F R E E R E G I S T R AT I O N genengnews.com/PrecisionDiagnostics View It Now! On Demand DURATION: 60 minutes COST: Complimentary Speakers Diana Merino, PhD Science Policy Analyst Friends of Cancer Research Jeffrey Waldron Executive Director Friends of Cancer Research E. Kelly Sullivan, PhD Solutions Manager N-of-One Produced with support from Webinars

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JUL-AUG 2019